[{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"CT1812","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"The Michael J. Fox Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ The Michael J. Fox Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Cognition Therapeutics \/ The Michael J. Fox Foundation"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"University of Miami Miller School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ University of Miami Miller School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ University of Miami Miller School of Medicine"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Sigma-2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ NIH","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ NIH"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ National Institute on Aging","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ National Institute on Aging"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Cognition Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cognition Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"CT1812","moa":"","graph1":null,"graph2":null,"graph3":"Cognition Therapeutics","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Cognition Therapeutics \/ Not Applicable","highestDevelopmentStatusID":null,"companyTruncated":"Cognition Therapeutics \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Cognition Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
